Document Detail

Current status of pulmonary thromboembolism--incidence, diagnosis, classification, pathogenesis, and treatment.
MedLine Citation:
PMID:  6198531     Owner:  NLM     Status:  MEDLINE    
The incidence of pulmonary thromboembolism in the total autopsied cases and the actual reported cases of pulmonary thromboembolism in Japan has gradually increased. Since there is no part of the history, physical examination or noninvasive laboratory findings that is specific, a tentative criteria for diagnosis of pulmonary thromboembolism is proposed based a scoring system. Pulmonary thromboembolism can be classified into 5 different types: (1) massive pulmonary thromboembolism, (2) recurrent or occult pulmonary thromboembolism, (3) diffuse pulmonary microthromboembolism, (4) submassive pulmonary thromboembolism, (5) pulmonary infarction. We have carried out a series of model experiments in order to clarify the mechanism of the development of pulmonary microthromboembolism and the production of pulmonary infarction. On the basis of this data, we suspect that hyperfibrinolysis, endothelial damages and activated permeability factors lead to the interstitial and alveolar edema in pulmonary microthromboembolism or severe hemorrhage in pulmonary infarction. The combination therapy of UK (480,000 units) and DS (3,000 mg) had two advantages: (1) inhibition of shortening of APTT, (2) economy of UK dosage. Laboratory monitoring for effective UK therapy showed a markedly reduced alpha 2PI to under 50% of normal levels and fibrinolysis associated with fibrinogenolysis. The therapeutic effects of heparin were assessed by prolonged APTT (45-250 sec) and elevated Anti-FXa activity (0.2-1.2 u/ml of plasma heparin concentration) as an indicator for the evaluation of anticoagulation activity and by normalized FPA, Fbg, FDP, Plg and AT III as an indicator for evaluation of antithrombolic activity.
H Hasegawa
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Japanese circulation journal     Volume:  48     ISSN:  0047-1828     ISO Abbreviation:  Jpn. Circ. J.     Publication Date:  1984 Jan 
Date Detail:
Created Date:  1984-03-05     Completed Date:  1984-03-05     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7806868     Medline TA:  Jpn Circ J     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  100-10     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antithrombin III / analysis
Blood Coagulation / drug effects
Dextrans / administration & dosage
Fibrin Fibrinogen Degradation Products / analysis
Fibrinogen / analysis
Heparin / administration & dosage
Middle Aged
Pulmonary Embolism / classification,  diagnosis*,  drug therapy,  epidemiology
Urokinase-Type Plasminogen Activator / administration & dosage
alpha-2-Antiplasmin / analysis
Reg. No./Substance:
0/Fibrin Fibrinogen Degradation Products; 0/alpha-2-Antiplasmin; 9000-94-6/Antithrombin III; 9001-32-5/Fibrinogen; 9004-54-0/Dextrans; 9005-49-6/Heparin; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Characterization of structural and immunological properties of specific domains of Friend ecotropic ...
Next Document:  The incidence of thromboembolism and the hemocoagulative background in patients with rheumatic heart...